MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4081/monaldi.2024.3079

Медицинская библиотека · Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace · 2024

Combination treatment with monoclonal antibodies for the management of severe asthma and immune-mediated inflammatory diseases: a comprehensive review.

Carriera Lorenzo, Caporuscio Sara, Fantò Marta, D'Abramo Alice, Puzio Genesio, Triolo Luca, Coppola Angelo

СтатьяОбзорПеревод в очереди

Аннотация

Biological drugs have revolutionized the management of severe asthma, and a tailored treatment approach has made it possible to consider remission as an achievable treatment target. The incidence of autoimmune diseases is increasing worldwide. Patients suffering from severe asthma, eligible for or already treated with an asthma-approved biologic agent, may suffer from another immune-mediated inflammatory disease (IMID) that could require the simultaneous use of a second monoclonal antibody. The real-life studies available in the literature describing the concurrent administration of an asthma-approved biologic agent with another biologic for a different immune disease, obtained through a systematic search on online databases based on monoclonal antibodies, were collected and analyzed. In this review, 26 articles were included according to the prespecified inclusion and exclusion criteria. All included papers were retrospective in nature. Study designs were case reports (n=18), case series (n=3), retrospective chart reviews (n=3), retrospective observational studies (n=1), and cohort studies (n=1). The study is intended to present, within the current literature, all the administered combinations of severe asthma-approved biologics with monoclonal antibodies for a different indication. Those were grouped according to the IMID for whom the second biologic agent, with a different mechanism of action, was prescribed. The combinations prescribed to the cohort of patients specifically treating uncontrolled severe asthma were more deeply evaluated in the discussion section, since an analysis of these therapeutic combinations deriving from real-life experiences may be useful to optimize the management of patients with severe asthma, ultimately leading to improved patient care and outcomes. Prospective registries and future studies are required to assess the safety and efficacy of combination therapies for severe asthmatic patients who suffer from an IMID.

Для цитирования: Carriera Lorenzo, Caporuscio Sara, Fantò Marta, D'Abramo Alice, Puzio Genesio, Triolo Luca, Coppola Angelo. Combination treatment with monoclonal antibodies for the management of severe asthma and immune-mediated inflammatory diseases: a comprehensive review.. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace. 2024. DOI: 10.4081/monaldi.2024.3079.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.